Skip to main content
Have a personal or library account? Click to login
Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness Cover

Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness

Radiology and Oncology
Volume 46 (2012): Issue 3 (September 2012)
By: ,  ,  ,  ,  ,   and    
Open Access
|Jun 2012
References

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics.2010;: 277-300.
    Open DOISearch in Google Scholar
  2. Brawley OW, Ankerst DP, Thompson IM. Screening prostate cancer.2009;: 264-73.
    Open DOISearch in Google Scholar
  3. Albersen PC. A challenge to contemporary management of prostate cancer.2009;: 12-3.
    Open DOISearch in Google Scholar
  4. Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Abdullah RSAR. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach.2009;: 180-6.
    Open DOISearch in Google Scholar
  5. Rojnik M, Jevnikar Z, Mirkovic B, Janes D, Zidar N, Kikelj D, et al. Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.2011;: 259-66.
    Open DOISearch in Google Scholar
  6. Ben-Haim S, Ell P. 18f-FDG PET and PET/CT in the evaluation of cancer treatment response.2009;: 88-99.
    Open DOISearch in Google Scholar
  7. Farsad M, Schiavina R, Franceschelli A, Sanguedolce F, Castellucci P, Bertaccini A, et al. Positron emission tomography in imaging and staging prostate cancer.2008;: 277-84.
    Open DOISearch in Google Scholar
  8. Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, et al. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome.2008;: 227-36.
    Open DOISearch in Google Scholar
  9. Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, et al. Correlation of Glut-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer.2006;: 2198-205.
    Open DOISearch in Google Scholar
  10. Ueda S, Kondoh N, Tsuda H, Yamamoto S, Asakawa H, Fukatsu K, et al. Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer.2008;: 384.
    Open DOISearch in Google Scholar
  11. Nakamura H, Hirata T, Kitamura H, Nishikawa J. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers.2009;: 304-10.
    Search in Google Scholar
  12. Backes H, Ullrick R, Neumaier B, Kracht L, Wienhard K, Hacobs AH. Noninvasive quantification of tumour proliferation in patients with high-grade glioma.2009;: 1960-7.
    Open DOISearch in Google Scholar
  13. Kawai N, Zhen HN, Miyake K, Yamamaoto Y, Nishiyama Y, Tamiya T. Prognostic value of pretreatment 18F-FDG PET in patients with primary central system lymphoma: SUV-based assessment.2010;: 225-32.
    Open DOISearch in Google Scholar
  14. American Joint Committee on Cancer. Prostate. In: Greene FL, Page DL, Fleming ID, editors.. 6th edition. New York: Springer; 2002. p. 309-16.
    Open DOISearch in Google Scholar
  15. Li X, Liu Q, Wang M, Jin X, Liu Q, Yao S, et al. C-11 choline PET/CT imaging for differenting malignant from benign prostate lesions.2008;: 671-6.
    Open DOISearch in Google Scholar
  16. Shukla-Dave A, Hricak H, Ishill N, Moskowitz CS, Drobnjak M, Reuter VE, et al. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles.2009;: 3842-9.
    Open DOISearch in Google Scholar
  17. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, et al. Expression patterns of potential therapeutic targets in prostate cancer.2005;: 619-28.
    Open DOISearch in Google Scholar
  18. Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, et al. Long term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.2008;: 1806-15.
    Open DOISearch in Google Scholar
  19. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial fingdings of PET with 2-deoxy-2[F-18]fluoro-D-glucose.1996;: 751-6.
    Open DOISearch in Google Scholar
  20. Hodolic M. Role of F-choline PET/CT in evaluation of patients with prostate carcinoma.2011;: 17-21.
    Open DOISearch in Google Scholar
  21. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography.2002;: 267-73.
    Open DOISearch in Google Scholar
  22. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [11C] Choline uptake with PET/CT for initial diagnosis of prostate cancer: relation to PSA levels, tumour stage, and antiandrogenic therapy.2008;: 1065-73.
    Open DOISearch in Google Scholar
  23. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F] fluorodeoxyglucose-positron emission tomography.2003;: 1337-40.
    Open DOISearch in Google Scholar
  24. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymphy-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.2007;: 423-9.
    Open DOISearch in Google Scholar
  25. Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G, et al. [11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.2008;: 689-95.
    Open DOISearch in Google Scholar
  26. Reske SN, Blumstein NM, Glatting G. [11C]Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.2008;: 9-17.
    Open DOISearch in Google Scholar
  27. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis.2005;: 1642-9.
    Search in Google Scholar
  28. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline.1998;: 990-5.
    Search in Google Scholar
  29. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma.2000;: 1415-9.
    Open DOISearch in Google Scholar
  30. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography.2002;: 18-23.
    Open DOISearch in Google Scholar
  31. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT.2006;: 1642-9.
    Search in Google Scholar
  32. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C] choline uptake in prostate cancer: a PET study.2004;: 317-24.
    Open DOISearch in Google Scholar
  33. Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy.2005;: 724-8.
    Open DOISearch in Google Scholar
  34. Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer.2005;: 668-73.
    Open DOISearch in Google Scholar
  35. Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.2009;: 1585-93.
    Open DOISearch in Google Scholar
  36. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.2001;: 555-65.
    Open DOISearch in Google Scholar
  37. Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore WF Jr. Gleason grading of prostate cancer: a predictor of survival.1985;: 223-7.
    Open DOISearch in Google Scholar
  38. Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer.2003;: 19-35.
    Open DOISearch in Google Scholar
  39. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome.2005;: 858-87.
    Open DOISearch in Google Scholar
  40. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.2009;: 888-93.
    Open DOISearch in Google Scholar
  41. Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study.2010;: 687-92.
    Open DOISearch in Google Scholar
  42. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesisi correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.1997;: 772-9.
    Open DOISearch in Google Scholar
  43. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.1987;: 177-82.
    Open DOISearch in Google Scholar
  44. Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, et al. Human epidermal receptor-2 expression in prostate cancer.2003;: 1087-97.
    Search in Google Scholar
  45. Savinainen KJ, Saramäki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.2002;: 339-45.
    Open DOISearch in Google Scholar
  46. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer.2000;: 1918-25.
    Open DOISearch in Google Scholar
  47. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.2006;: 123-30.
    Open DOISearch in Google Scholar
  48. Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.2010;: 1553-60.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10019-012-0034-y | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 179 - 188
Published on: Jun 19, 2012
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
prostate cancer,
aggressiveness,
PET/CT,
choline
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2012 Ji Chen, Yong Zhao, Xin Li, Peng Sun, Muwen Wang, Ridong Wang, Xunbo Jin, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 46 (2012): Issue 3 (September 2012)
Next article